Novo Nordisk AS - Company Profile
Powered by
All the data and insights you need on Novo Nordisk AS in one report.
- Save hours of research time and resources with
our up-to-date Novo Nordisk AS Strategy Report
- Understand Novo Nordisk AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View more- Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization
- Top 10 Pharmaceutical Companies in the World in 2022 by Market Capitalization
- Top 10 Pharma Companies in Europe in 2021 by R&D Expenditure
- Top 10 Big Biopharma Companies (Large Pharma & Large Biotech) in Europe in 2021 by Revenues
Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for haemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Novo Nordisk AS premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Diabetes Delivery Systems: | Rivfloza |
Insulin Pens | Tresiba |
Injection Needles | Ryzodeg |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Plans/Strategy | In March, the company announced its plans to acquire Cardior Pharmaceuticals, a biotech company. |
2024 | Regulatory Approval | In March, the company secured expanded approval from the US FDA for Wegovy to treat stroke and heart attacks. |
2024 | Plans/Strategy | In March, Novo Holdings announced its plans to open a new office in Mumbai, India. |
Competitor Comparison
Key Parameters | Novo Nordisk AS | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
---|---|---|---|---|---|
Headquarters | Denmark | United States of America | Switzerland | United States of America | United States of America |
City | Bagsvaerd | New Brunswick | Basel | Kenilworth | New York |
State/Province | - | New Jersey | - | New Jersey | New York |
No. of Employees | 63,370 | 131,900 | 103,605 | 72,000 | 88,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Helge Lund | Chairman | Executive Board | 2018 | 62 |
Lars Fruergaard Jorgensen | President; Chief Executive Officer | Senior Management | 2017 | 58 |
Karsten Munk Knudsen | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 53 |
Marcus Schindler | Chief Scientific Officer; Executive Vice President - Research & Early Development | Senior Management | 2021 | 58 |
Henrik Poulsen | Vice Chairman | Executive Board | 2021 | 57 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward